379 reports of this reaction
2.3% of all MESNA INJECTION reports
#5 most reported adverse reaction
THROMBOCYTOPENIA is the #5 most commonly reported adverse reaction for MESNA INJECTION, manufactured by Gland Pharma Limited. There are 379 FDA adverse event reports linking MESNA INJECTION to THROMBOCYTOPENIA. This represents approximately 2.3% of all 16,183 adverse event reports for this drug.
Patients taking MESNA INJECTION who experience thrombocytopenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THROMBOCYTOPENIA is a less commonly reported adverse event for MESNA INJECTION, but still significant enough to appear in the safety profile.
In addition to thrombocytopenia, the following adverse reactions have been reported for MESNA INJECTION:
The following drugs have also been linked to thrombocytopenia in FDA adverse event reports:
THROMBOCYTOPENIA has been reported as an adverse event in 379 FDA reports for MESNA INJECTION. This does not prove causation, but indicates an association observed in post-market surveillance data.
THROMBOCYTOPENIA accounts for approximately 2.3% of all adverse event reports for MESNA INJECTION, making it a notable side effect.
If you experience thrombocytopenia while taking MESNA INJECTION, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.